Key Lessons & Opportunities in applying NCA and PopPK to ADCs
Applying NCA and PopPK to ADCs helps decode complex PK, balance DAR effects, and guide…
CertaraOctober 24, 2025
AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success
Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…
CertaraOctober 21, 2025
Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraOctober 15, 2025
RAPS Sponsored Webinar: Planning and Preparing Regulatory Submissions Using Top-down Messaging
Access our on-demand webinar and explore proven strategies to develop consistent, high-impact regulatory submission messages.
CertaraOctober 9, 2025
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
CertaraOctober 2, 2025
Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
CertaraSeptember 22, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraSeptember 17, 2025
